HbA1c levels and all-cause mortality in type 2 diabetic patients: Epidemiological evidence of the need for personalised therapeutic targets

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 4, 2013, Pages 300-306

  Monami, M ^a   Vitale, V ^b   Lamanna, C ^b   Bartoli, N ^a   Martelli, D ^a   Zannoni, S ^a   Antenore, A ^a   Toffanello, G ^a   Marchionni, N ^a   Mannucci, E ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Case control study; Diabetes; Glycated haemoglobin; Individualised therapy; Mortality; Personalised therapy

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

AGE; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; FRAIL ELDERLY; HUMAN; ITALY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; FRAIL ELDERLY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; INSULIN; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84875078117     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.01.003     Document Type: Article

References (24)

1. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
2. NICE-SUGAR Study Investigators, Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297.
3. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
4. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
5. Colayco D.C., Niu F., McCombs J.S., Cheetham T.C. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011, 34:77-83.
6. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
7. Eeg-Olofsson K., Cederholm J., Nilsson P.M., Zethelius B., Svensson A.M., Gudbjörnsdóttir S., et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010, 268:471-482.
8. Elley C.R., Kenealy T., Robinson E., Drury P.L. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med 2008, 25:1295-1301.
9. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
10. Type 2 diabetes: the management of type 2 diabetes. National Institute for Health and Clinical Excellence Available from: http://www.nice.org.uk/CG66.
11. Chonchol M., Katz R., Fried L.F., Sarnak M.J., Siscovick D.S., Newman A.B., et al. Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly. Nutr Metab Cardiovasc Dis 2010, 20:15-21.
12. Chalmers J., MacMahon S., Mancia G., Whitworth J., Beilin L., Hansson L., et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. guidelines sub-committee of the World Health Organization. ClinExpHypertens 1999, 21:1009-1060.
13. Charlson M., Szatrowski T., Peterson T., Gold J. Validation of a combined comorbidity index. J ClinEpidemiol 1994, 47:1245-1251.
14. Timmer J.R., Hoekstra M., Nijsten M.W., van der Horst I.C., Ottervanger J.P., Slingerland R.J., et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011, 124:704-711.
15. Nandish S., Bailon O., Wyatt J., Smith J., Stevens A., Lujan M., et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence?. CurrAtheroscler Rep 2011, 13:123-128.
16. Lebovitz H.E. Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diab Care 2011, 34(Suppl. 2):S225-S230.
17. Rensing K., Reuwer A.Q., Arsenault B.J., von der Thüsen J.H., Hoekstra J.B., Kastelein J.J., et al. Reducing cardiovascular disease risk in diabetic patients with established macrovascular disease: can insulin be too much of a good thing?. DOM 2011, Accepted Article. 10.1111/j.1463-1326.2011.01469.x.
18. Currie C.J., Johnson J. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. DOM 2011, Accepted Article. 10.1111/j.1463-1326.2011.01469.x.
19. Mannucci E., Monami M., Lamanna C., Gori F., Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009, 19:604-612.
20. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
22. The action to control cardiovascular risk in diabetes study group effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
23. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
24. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutrition, Metab Cardiovasc Dis 2009, 19:365-377.